Su-11248 Sugen.
SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.